Best Small Cap Stocks To Consider - October 19th

Key Points

• MarketBeat highlights seven small-cap stocks to watch, including Spring Valley Acquisition, Rani Therapeutics, and Lithium Americas, all exhibiting significant trading volume recently.
• Rani Therapeutics is focusing on its RaniPill capsule, an innovative platform for orally administering biologics, targeting diverse medical applications.
• Lithium Americas is active in the exploration and development of lithium properties, particularly through its key Thacker Pass project in Nevada.

Spring Valley Acquisition, Rani Therapeutics, Veritex, Artiva Biotherapeutics, Inflection Point Acquisition Corp. II, SEALSQ, and Lithium Americas are the seven Small Cap stocks to watch today, according to MarketBeat's stock screener tool. Small-cap stocks are shares of companies with relatively small market capitalizations—typically about $300 million to $2 billion, though exact cutoffs vary by index provider. Investors consider them higher-growth but also higher-risk and less liquid than large-cap stocks, meaning they can offer bigger upside potential but greater volatility and company-specific risk. These companies had the highest dollar trading volume of any Small Cap stocks within the last several days.

Spring Valley Acquisition (SV)

Read Our Latest Research Report on SV

Rani Therapeutics (RANI)

Rani Therapeutics Holdings, Inc. operates as a clinical stage biotherapeutics company that develops orally administered biologics for patients, physicians, and healthcare systems in the United States. The company develops the RaniPill capsule, a drug-agnostic oral delivery platform to deliver a variety of drug substances, including oligonucleotides, peptides, proteins, and antibodies.

Read Our Latest Research Report on RANI

Veritex (VBTX)

Veritex Holdings, Inc. operates as the bank holding company for Veritex Community Bank that provides various commercial banking products and services to small and medium-sized businesses, and professionals. The company accepts deposit products include demand, savings, money market, and time accounts.

Read Our Latest Research Report on VBTX

Artiva Biotherapeutics (ARTV)

Artiva Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing natural killer (NK) cell-based therapies for patients suffering from autoimmune diseases and cancers. The company's lead product candidate is AB-101, an off-the-shelf NK cell therapy for patients with autoimmune diseases and cancers, such as lupus nephritis, rheumatoid arthritis, pemphigus vulgaris, the anti-neutrophil cytoplasmic antibody-associated vasculitis subtypes granulomatosis with polyangiitis/microscopic polyangiitis, systemic lupus erythematosus, and B-cell-non-Hodgkin lymphoma.

Read Our Latest Research Report on ARTV

Inflection Point Acquisition Corp. II (IPXX)

Read Our Latest Research Report on IPXX

SEALSQ (LAES)

SEALSQ Corp, together with its subsidiaries, designs, develops, and markets semiconductor chips in Europe, the Middle East, Africa, North America, the Asia Pacific, and Latin America. It offers semiconductors, such as VaultIC secure elements, secure arm platform, and smart card reader chips; identity provisioning services, such as IoT device provisioning and chip provisioning; and managed PKI for IoT solutions and trust services.

Read Our Latest Research Report on LAES

Lithium Americas (LAC)

Lithium Americas Corp. engages in the exploration and development of lithium properties in the United States and Canada. It holds a 100% interest in the Thacker Pass project located in northern Nevada, as well as investments in exploration properties in the United States and Canada. Lithium Americas Corp.

Read Our Latest Research Report on LAC